Rosetta Regains US Rights to miRNA Cancer Diagnostics, Addresses QC Issue at Diagnostics Lab | GenomeWeb

This article has been updated from a version posted Nov. 29 to include information from the company's third-quarter conference call.

By Doug Macron

Rosetta Genomics last week announced that it has regained the US market rights to its three flagship cancer diagnostics, settling a nearly six-month dispute with one-time partner Prometheus Laboratories.

In exchange, Rosetta will pay Prometheus $3.1 million over the next year and a half.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.